Together, these results define a molecular mechanism for enhanced COX-2 expression in prostate cancer cells, and suggest a means by which NE-differentiated tumor cells and their bioactive neuropeptides may contribute to disease progression. This evidence concerns the gene PTGS2 and neoplasm.